{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer%2C+Breast+Neoplasms&page=14",
    "query": {
      "condition": "Breast Cancer, Breast Neoplasms",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 7049,
    "total_pages": 705,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer%2C+Breast+Neoplasms&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Breast+Cancer%2C+Breast+Neoplasms&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T18:19:46.279Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00426556",
      "title": "Efficacy and Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 88,
      "start_date": "2007-07",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2015-12-28",
      "last_synced_at": "2026-10-14T18:19:46.279Z",
      "location_count": 11,
      "location_summary": "*see Various Departments*, California • Fountain Valley, California • Loma Linda, California + 8 more",
      "locations": [
        {
          "city": "*see Various Departments*",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Davie",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00426556"
    },
    {
      "nct_id": "NCT05143229",
      "title": "Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Alpelisib",
          "type": "DRUG"
        },
        {
          "name": "Sacituzumab govitecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2022-03-28",
      "completion_date": "2026-12",
      "has_results": false,
      "last_update_posted_date": "2026-05-01",
      "last_synced_at": "2026-10-14T18:19:46.279Z",
      "location_count": 7,
      "location_summary": "Fairway, Kansas • Overland Park, Kansas • Westwood, Kansas + 2 more",
      "locations": [
        {
          "city": "Fairway",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Westwood",
          "state": "Kansas"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05143229"
    },
    {
      "nct_id": "NCT04660929",
      "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HER2-positive",
        "Adenocarcinoma",
        "Bile Duct Cancer",
        "Biliary Tract Cancer",
        "Bladder Cancer",
        "Breast Cancer",
        "Breast Neoplasm",
        "Carcinoma, Ductal",
        "Carcinoma, Hepatocellular",
        "Cancer",
        "Lung Cancer, Non-Small-Cell",
        "Carcinoma, Ovarian Epithelial",
        "Carcinoma, Small Cell",
        "Carcinoma, Squamous",
        "Carcinoma, Transitional Cell",
        "Colorectal Cancer",
        "Esophagogastric Junction Neoplasms",
        "Inflammatory Breast Cancer",
        "Stomach Neoplasms",
        "Malignant Neoplasms",
        "Ovarian Neoplasms",
        "Pancreatic Cancer",
        "HER2-positive Solid Tumors",
        "HER2-positive Breast Cancer",
        "HER2-positive Gastric Cancer",
        "HER-2 Protein Overexpression",
        "HER-2 Gene Amplification",
        "Prostate Cancer",
        "Head and Neck Cancer",
        "Endometrial Cancer",
        "Lung Cancer, Small Cell"
      ],
      "interventions": [
        {
          "name": "CT-0508",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Carisma Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2021-02-02",
      "completion_date": "2024-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-12-18",
      "last_synced_at": "2026-10-14T18:19:46.279Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Chapel Hill, North Carolina • Portland, Oregon + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04660929"
    },
    {
      "nct_id": "NCT00593827",
      "title": "Phase II Trial of Weekly or Every 3-week Ixabepilone for Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "R-Pharm",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 176,
      "start_date": "2008-05",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2016-03-10",
      "last_synced_at": "2026-10-14T18:19:46.279Z",
      "location_count": 57,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Sedona, Arizona + 49 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sedona",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Murrieta",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00593827"
    },
    {
      "nct_id": "NCT01603303",
      "title": "Preventing Sexual Dysfunction With Aromatase Inhibitors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Questionnaires",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Education Materials",
          "type": "OTHER"
        },
        {
          "name": "Luvena",
          "type": "OTHER"
        },
        {
          "name": "Hyalo-Gyn",
          "type": "OTHER"
        },
        {
          "name": "Vaginal Lubricant",
          "type": "OTHER"
        },
        {
          "name": "Interactive Internet-Based Website",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Telephone Counseling.",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 187,
      "start_date": "2012-12-05",
      "completion_date": "2017-08-11",
      "has_results": false,
      "last_update_posted_date": "2017-08-18",
      "last_synced_at": "2026-10-14T18:19:46.279Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01603303"
    },
    {
      "nct_id": "NCT07672431",
      "title": "Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Triple Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "TheraBionic P1",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Barbara Ann Karmanos Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "22 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "22 Years and older · Female only"
      },
      "enrollment_count": 24,
      "start_date": "2026-09",
      "completion_date": "2028-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-06-29",
      "last_synced_at": "2026-10-14T18:19:46.279Z",
      "location_count": 1,
      "location_summary": "Detroit, Michigan",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07672431"
    },
    {
      "nct_id": "NCT07749586",
      "title": "A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor"
      ],
      "interventions": [
        {
          "name": "ARV-6723",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        },
        {
          "name": "SOC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Arvinas Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 499,
      "start_date": "2026-07-29",
      "completion_date": "2032-03-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-10-14T18:19:46.279Z",
      "location_count": 4,
      "location_summary": "New York, New York • Huntersville, North Carolina • San Antonio, Texas + 1 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Huntersville",
          "state": "North Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Fairfax",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07749586"
    },
    {
      "nct_id": "NCT02275754",
      "title": "Redes III Patient Navigator Qol Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Breast Cancer",
        "Prostate Cancer",
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "PN+LCNC",
          "type": "BEHAVIORAL"
        },
        {
          "name": "PN Only",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2010-11",
      "completion_date": "2017-12-31",
      "has_results": false,
      "last_update_posted_date": "2018-10-02",
      "last_synced_at": "2026-10-14T18:19:46.279Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • San Antonio, Texas",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02275754"
    },
    {
      "nct_id": "NCT00227656",
      "title": "Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "PEG-interferon alfa-2a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Capecitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2005-09",
      "completion_date": "2006-11",
      "has_results": false,
      "last_update_posted_date": "2012-12-11",
      "last_synced_at": "2026-10-14T18:19:46.279Z",
      "location_count": 4,
      "location_summary": "Wichita, Kansas • Grand Rapids, Michigan • Springfield, Missouri + 1 more",
      "locations": [
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        },
        {
          "city": "Springfield",
          "state": "Missouri"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00227656"
    },
    {
      "nct_id": "NCT03447886",
      "title": "Understanding Barriers to Initiation and Adherence to Endocrine Therapy in Young Breast Cancer Survivors of Diverse Backgrounds",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Phone interview",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 17,
      "start_date": "2018-03-09",
      "completion_date": "2018-08-27",
      "has_results": false,
      "last_update_posted_date": "2021-06-11",
      "last_synced_at": "2026-10-14T18:19:46.279Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03447886"
    }
  ]
}